Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XAU2
- Development stage
- Unknown
- Lead developer
- Xenothera
- Modality
- Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
XAU2 is a glyco-humanized polyclonal antibody (GH-pAb) candidate developed by Xenothera. It is produced using a proprietary platform that generates polyclonal antibodies in animals, such as pigs, which have been genetically modified to lack the immunogenic sugar N-glycolylneuraminic acid (Neu5Gc). This 'glyco-humanization' process is designed to reduce the risk of adverse immune reactions, including serum sickness, in human recipients. While the specific therapeutic target and indication for XAU2 have not been publicly disclosed, the GH-pAb platform is intended to provide a broad, multi-epitope immune response. Pipeline records indicate the program was in the Preclinical/Phase 1 stage around 2015-2016.
- Other names
- XAU2-Xenothera-glyco-humanized polyclonal antibodyXAU-2-Xenothera-glyco-humanized polyclonal antibodyXAU 2-Xenothera-glyco-humanized polyclonal antibodyGH-pAb
Beyond the preview
Go deeper on XAU2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XAU2.